科伦药业 reported revenue of ¥8.84B for the period ended 2026-06-30, -2.7% year on year. Net income was ¥1.43B, a 16.1% net margin on a 47.6% gross margin. The largest revenue line is 非输液 at 53% of the total. Free cash flow for the period was ¥1.83B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥8.84B | -2.7% |
| Gross profit | ¥4.20B | — |
| Operating income | ¥0.90B | — |
| Net income | ¥1.43B | +28.0% |
| Gross margin | 47.6% | Net margin 16.1% |
| Revenue Q/Q | +7.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 非输液 | ¥4.65B | 52.6% |
| 输液 | ¥3.56B | 40.3% |
| 研发项目 | ¥0.32B | 3.6% |
| 其他(补充) | ¥0.31B | 3.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥4.63B | 52.4% |
| R&D | ¥1.21B | 13.7% |
| SG&A | ¥2.10B | 23.8% |
| Tax & other | ¥-0.53B | -6.0% |
| Item | Amount |
|---|---|
| Total assets | ¥41.49B |
| Total liabilities | ¥11.66B |
| Shareholders' equity | ¥29.82B |
| Equity / assets | 71.9% |
| Operating cash flow | ¥2.09B |
| Capital expenditure | ¥0.26B |
| Free cash flow | ¥1.83B |
| Cash conversion (OCF / net income) | 164% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
赣锋锂业 ・ 沪电股份 ・ 天齐锂业 ・ 立讯精密 ・ 荣盛石化 ・ 天山铝业 ・ 巨人网络 ・ 比亚迪 ・ 领益智造 ・ 世纪华通 ・ 光启技术 ・ 卫星化学
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies